Skip to main content
| News

Lyfegen collaborating with Johnson & Johnson

03.08.2021

The Basel-based startup Lyfegen has developed a platform for value-based healthcare. This should provide improved outcomes for patients and result in cost-savings. Lyfegen teamed up with Johnson & Johnson for the implementation.

Girisha Fernando, Frederico Braga, Michel Mohler and Nico Mros from Lyfegen HealthTech AG (img: Lyfegen)

The concept of value-based healthcare is rooted in the definition of patient outcome per franc spent. By aligning all processes with this approach, the aim is to improve patient outcomes and reduce healthcare costs at the same time. Founded in 2018, the Basel-based company Lyfegen has developed a platform that can be used to implement value-based healthcare processes. Lyfegen teamed up with the life sciences company Johnson & Johnson Switzerland and a “leading” Swiss hospital for the implementation process, which has now been brought to a close, further details of which can be found in a press release.

The patented Lyfegen platform automates the collection and analysis of all patient-related data. In this way, the aim is to achieve transparency with regard to the contract content, expenses and healthcare outcomes. Lyfegen describes the platform as a “blueprint” from which global hospitals, health insurance companies and life sciences providers all stand to benefit. “Covid-19 has shown us the urgent need for a more sustainable healthcare system”, comments Girisha Fernando, CEO of Lyfegen, in the press release. “With the implementation of value-based healthcare agreements on the Lyfegen platform, we are extremely proud to help Johnson & Johnson and hospitals to accelerate the transition to value-based healthcare and improve patient health outcomes at reduced cost”.

For Lyfegen, the agreed partnership represents a key “milestone”, the press release explains further. The Basel-based startup recently opened up a new investment round.

Share this article

Sign up to receive our newsletter in your inbox.

You may also be interested in

Gamma Technologies acquires ProFEMAG portfolio
Advanced Manufacturing/AI, Basel Area Business & Innovation, ICT, Innovation, Invest

Gamma Technologies acquires ProFEMAG portfolio

The Basel-based firm ProFEMAG AG has sold its FEMAG software for electrical machine applications to Gamma Technologies. The company based...

Read More
Databaum establishes headquarters in Basel
Basel Area Business & Innovation, ICT, Innovation, Invest, Life Sciences / biotech

Databaum establishes headquarters in Basel

Databaum is establishing its headquarters in Basel and plans to grow from its location there. The startup provides the agricultural...

Read More
Clinerion launches patient information platform
Basel Area Business & Innovation, Digital Health, ICT, Innovation, Invest, Life Sciences / biotech

Clinerion launches patient information platform

Basel-based Clinerion is introducing its machine learning platform. It comprises a global network of hospitals and enables researchers to recognize...

Read More
New innovation campus opens in the Basel Area
Basel Area Business & Innovation, Innovation, Invest, Life Sciences / biotech, Switzerland Innovation Park

New innovation campus opens in the Basel Area

The Main Campus of the Switzerland Innovation Park Basel Area was officially opened on October 29. In his speech, Federal...

Read More
Sumitovant acquires all shares in Myovant
Basel Area Business & Innovation, Innovation, Invest, Life Sciences / biotech

Sumitovant acquires all shares in Myovant

Sumitovant is in the process of making Basel-based Myovant Sciences a wholly owned subsidiary by acquiring a 100 percent shareholding...

Read More
VectivBio raises 125 million US dollars in stock sale
Basel Area Business & Innovation, Innovation, Invest, Life Sciences / biotech

VectivBio raises 125 million US dollars in stock sale

VectivBio has announced the closing of the subscription offer for 16,700,000 ordinary shares. The Basel-based biotechnology firm has generated gross...

Read More
1 2 3 29

Do you have a question? We'd like to hear from you.